---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-000651"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:29:56.025738+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics reports preliminary Q4 revenue $8.1-8.4M, up 27-33% YoY

## Summary
- Full-year 2022 revenue expected $27.7-28.0M, up 54-56% vs 2021; exceeded initial guidance ranges.
- Installed base of Saphyr systems reached 240 at year-end, a 46% increase over 2021.
- Completed acquisition of Purigen Biosystems to accelerate OGM adoption via improved DNA prep.
- Planned commercial launch of next-gen OGM system in H1 2023; NxClinical v7.0 release also expected H1 2023.

## SEC filing metadata
- accession: 0001140361-23-000651
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/brhc10046334_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-000651
- JSON: https://secwatch.observer/filing/0001140361-23-000651.json
- Plain text: https://secwatch.observer/filing/0001140361-23-000651.txt

## Key facts
- Earnings Releases
  Bionano Genomics, Inc. reported the year ended December 31, 2022 results: revenue $27.7 million and $28.0 million.
  - Period: the year ended December 31, 2022
  - Revenue: $27.7 million and $28.0 million
  - Result: preliminary results
  source text: Full year 2022 revenue is expected to be in the range of $27.7 million and $28.0 million, an estimated increase of between 54% and 56% compared to 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm
- Earnings Releases
  Bionano Genomics, Inc. reported the fourth quarter of 2022 results: revenue $8.1 million to $8.4 million.
  - Period: the fourth quarter of 2022
  - Revenue: $8.1 million to $8.4 million
  - Result: preliminary results
  source text: Revenues for the fourth quarter 2022 are expected to be in the range of $8.1 million to $8.4 million , an estimated increase of 12% to 16% compared to $7.2 million in the third quarter of 2022 and an estimated increase of 27% to 33% compared to the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.